• BICO reaffirmed its long-term target for double-digit organic growth in constant currencies under its 2030 strategy.
• The profitability target remains an EBITDA margin less capitalized development costs above 10%; net debt to EBITDA must remain below 3.0x.
• Resources will shift toward Precision Biology, reducing exposure to large, customized lab automation projects that have weighed on profitability.
• The current serviceable market is estimated at approximately USD 1.5 billion, with compound annual growth of approximately 4–7%.
• New long-term financial targets will be set once current targets are achieved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BICO Group AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.